Ubiquitin proteasome pathway: Implications and advances in cancer therapy

Surgical Oncology

Volumn 10, Issue 1-2, 2001, Pages 43-52

  Shah, Shimul A ^a   Potter, Michael W ^a   Callery, Mark P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Chemoresistance; NF B; p21; p27; p53

Indexed keywords

ACETYLLEUCYLLEUCYLNORLEUCINAL; ALDEHYDE DERIVATIVE; ANGIOGENESIS INHIBITOR; BENZYLOXYCARBONYLISOLEUCYL O TERT BUTYLGLUTAMYLALANYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLNORVALINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CELL CYCLE PROTEIN; CISPLATIN; CVT 634; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; MG 115; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; PS 273; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE; DISEASE COURSE; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 0035180374     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(01)00018-4     Document Type: Article

References (100)

1. Proteasome inhibitors: Valuable new tools for cell biologists
2. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquination
3. The ubiquitin system
4. Proteasomes: Destruction as a programme
5. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors
6. The Ubiquitin-proteasome proteolytic pathway
7. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes
8. The multicatalytic proteinase complex, a major extralysosomal proteolytic system
9. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
10. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway
11. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation
12. Catalysis by a multiprotein IkappaB kinase complex
13. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
14. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
15. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells
16. Mechanistic studies on the activation of the proteasome by lactacystin: A central role for clasto-lactacystin beta-lactone
17. Inhibition of NF-κB activation in vitro and in vivo: Role of 26S proteosome
18. α-aminoboronic acid derivatives: Effective inhibitors of aminopeptdiases
19. The selective inhibition of thrombin by peptides of bioarginine
20. A new peptide boronic acid inhibitor of elastase-induced lung injury in hamsters
21. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: Identification of a cyclin species containing a B-N bond
22. Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo
23. Immunosuppressive boronic acid dipeptides: Correlation between conformation and activity
24. The proteasome inhibitor PS-341 in cancer therapy
25. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
26. Cancer cell cycles
27. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
28. WAF1, a potential mediator of p53 tumor suppression
29. Degradation of nuclear oncoproteins by the ubiquitin system in vitro
30. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway
31. In vivo ubiquination and proteasome-mediated degradation of p53
32. Mechanism of p53 degradation
33. Dial 9-1-1 for p-53: Mechanisms of p53 activation by cellular stress
34. UV radiation stimulates levels of p53 cellular antigen in nontransformed mouse cells
35. Participation of p53 protein in the cellular response to DNA damage
36. Apoptosis induction resulting from proteasome induction
37. Proteasome inhibitors: A novel class of potent and effective antitumor agents
38. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
39. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
40. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
41. Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells
42. Cyclin is degraded by the ubiquitin pathway
43. Dominoes and clocks: The union of two views of the cell cycle
44. The role of cyclin synthesis, modification and destruction in the control of cell division
45. The B-type cyclin kinase inhibitor p40 controls the G1 to S transition in S. cerevisiae
46. 26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
47. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
48. The ubiquitin-mediated pathway as a therapeutic area
49. DNA damage induces phosphorylation of the amino terminus of p53
50. The cyclosome, a large complex containing cyclin selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis
51. p27, a novel inhibitor of G1-cyclin-CDK protein kinase activity, is related to p21
52. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
53. Decreased levels of the cell cycle inhibitor p27 Kip1 protein: Prognostic implications in breast cancer
54. Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells
55. WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer
56. Control of programmed cyclin destruction in a cell-free system
57. Both cyclin AΔ60 and BΔ97 are stable and arrest cells in M-phase, but only cyclin BΔ97 turns on cyclin destruction
58. Detailed analysis of cell cycle kinetics upon proteasome inhibition
59. The mechanisms and functions of ATP-dependent proteases in bacterial and animal cells
60. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells
61. Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator tax and the proteasome
62. Inhibitors of the proteasome pathway interfere with the induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB
63. The Ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
64. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
65. Constitutive NF-κB/RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
66. Aberrent NF-κB/Rel expression and pathogenesis of breast cancer
67. Enhanced degradation of IκBα contributes to endogenous activation of NF-κB in Hs294 T melanoma cells
68. The nuclear factor κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
69. New classes of tumor promoters: Telecidin, aplysiatoxin, and palytoxin
70. Okadaic acid: An additional non-phorbal-12-tetradecanoate-13-acetate-type tumor promoter
71. An essential role for NF-κB in preventing TNF-α-induced cell death
72. Suppression of TNF-α-induced apoptosis by NF-κB
73. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
74. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells
75. WAF1 in human melanoma cells
76. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors
77. Activation of the cell death program by inhibition of proteasome function
78. Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells
79. Proteasomes play an essential role in thymocyte apoptosis
80. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons
81. Apoptosis induced by anticancer drugs
82. Apoptosis. Its significance in cancer and cancer therapy
83. Apoptosis in cancer therapy: Crossing the threshold
84. Regulatory balances in cell proliferation and cell death during oncogenesis in transgenic mice
85. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
86. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
87. NF-κB antiapoptosis: Induction of TRAF1, TRAF2, c-IAP1 and c-IAP2 to suppress caspase-8 activation
88. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis cIAP2 is under NF-κB control
89. NF-κB activation by campthecin
90. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
91. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors
92. Prevention of programmed cell death in Caenorhabitis elegans by human Bcl-2
93. Bcl-2 family proteins: Relative importance as determinants of chemoresistance in cancer
94. Cell and environment interactions in tumor microregions: The multicell spheroid model
95. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
96. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
97. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
98. Apoptosis and dilemna of cancer chemotherapy
99. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs